Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | INTS |
---|---|---|
10:47 ET | 1916 | 3.2 |
10:58 ET | 200 | 3.3 |
11:12 ET | 1000 | 3.2428 |
12:01 ET | 100 | 3.23 |
12:26 ET | 138 | 3.2299 |
01:13 ET | 600 | 3.23 |
01:15 ET | 100 | 3.265 |
01:29 ET | 100 | 3.2818 |
01:31 ET | 800 | 3.2363 |
02:12 ET | 7022 | 3.3985 |
03:10 ET | 2000 | 3.3853 |
03:17 ET | 300 | 3.35 |
03:21 ET | 442 | 3.325 |
03:50 ET | 177 | 3.325 |
04:00 ET | 611 | 3.39 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Intensity Therapeutics Inc | 46.7M | -3.1x | --- |
CalciMedica Inc | 47.0M | -1.9x | --- |
OKYO Pharma Ltd | 36.5M | -1.5x | --- |
Immix Biopharma Inc | 47.2M | -2.0x | --- |
Rallybio Corp | 46.1M | -0.7x | --- |
Xilio Therapeutics Inc | 47.5M | -0.5x | --- |
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. The Company is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead investigational product candidate, INT230-6, is designed for direct intratumoral injection. Its INT230-6 is primarily comprised of three components: cisplatin, vinblastine sulfate and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of Phase III open-label, randomized study testing the superiority of INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, and Phase II/III clinical study in metastatic triple negative breast cancer.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $46.7M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 13.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.10 |
Book Value | $0.96 |
P/E Ratio | -3.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.